公开(公告)号：EP2172566B2

公开(公告)日：2022-05-18

申请号：EP09012809.1

申请日：2008-07-17

发明人： Zichi, Dominic ,  Wilcox, Sheri K. ,  Bock, Chris ,  Schneider, Daniel J. ,  Eaton, Bruce ,  Gold, Larry

IPC分类号： C12Q1/6811 ,  C12N15/115

公开(公告)号：EP3478843A1

公开(公告)日：2019-05-08

申请号：EP17740201.3

申请日：2017-06-30

申请人： Somalogic, Inc.

发明人： CARTER, Jeff ,  GAWANDE, Bharat ,  JANJIC, Nebojsa ,  SCHNEIDER, Daniel

IPC分类号： C12N15/115 ,  C12N15/11 ,  A61K31/7115

公开(公告)号：EP2831278B1

公开(公告)日：2019-05-08

申请号：EP13767724.1

申请日：2013-03-28

申请人： Somalogic, Inc.

发明人： JARVIS, Thale C. ,  ROHLOFF, John C. ,  GELINAS, Amy D. ,  ZHANG, Chi ,  DROLET, Daniel W. ,  WAUGH, Sheela M. ,  JANJIC, Nebojsa

IPC分类号： C12Q1/68 ,  C12N15/115

公开(公告)号：EP3330277A2

公开(公告)日：2018-06-06

申请号：EP18153515.4

申请日：2014-11-19

申请人： Somalogic, Inc.

发明人： ROHLOFF, John ,  JANJIC, Nebojsa ,  GAWANDE, BharatNathu

IPC分类号： C07H19/06 ,  C07H19/073 ,  C07H19/10 ,  C07H21/00 ,  C07H1/00 ,  C12Q1/6811

CPC分类号： C07H19/06 ,  C07H1/00 ,  C07H19/073 ,  C07H19/10 ,  C07H21/00 ,  C12Q1/6811 ,  C12Q2525/117

摘要： Described herein are 5-position modified cytosines of formula I, nucleotides and nucleosides as well as phosphoramidites and triphosphates derivatives thereof. Further provided are methods of making and using the same, and compositions and uses of the modified nucleosides as part of a nucleic acid molecule (e.g., aptamer). Those modified nucleotides, bearing an N-substituted-carboxamine group at the 5 -position, are valuable tools for improving in vitro selection of protein-binding aptamers (SELEX process).

wherein
R is independently a -(CH 2 ) n , wherein n is 0,1,2,3,4,5,6,7,8,9 or 10;
R X1 is independently selected from the group consisting of

公开(公告)号：EP3284832A3

公开(公告)日：2018-03-07

申请号：EP17181688.7

申请日：2008-07-17

申请人： Somalogic, Inc.

发明人： ZICHI, Dominic ,  WILCOX, Sheri K. ,  BOCK, Chris ,  SCHNEIDER, Daniel J. ,  EATON, Bruce ,  GOLD, Larry

IPC分类号： C12Q1/68 ,  C12N15/115 ,  C12Q1/6811 ,  C12N15/10 ,  C12N15/11

CPC分类号： C12Q1/6811 ,  C12N15/1048 ,  C12N15/111 ,  C12N15/115 ,  C12N2310/16 ,  C12N2320/13 ,  C12Q2541/101 ,  C12Q2525/205 ,  C12Q2525/117

摘要： The present disclosure describes improved SELEX methods for producing aptamers that are capable of binding to target molecules and improved photoSELEX methods for producing photoreactive aptamers that are capable of both binding and covalently cross linking to target molecules. Specifically, the present disclosure describes methods for producing aptamers and photoaptamers having slower dissociation rate constants than are obtained using prior SELEX and photoSELEX methods. The disclosure further describes aptamers and photoaptamers having slower dissociation rate constants than those obtained using prior methods. In addition, the disclosure describes aptamer constructs that include a variety of functionalities, including a cleavable element, a detection element, and a capture or immobilization element.

公开(公告)号：EP2558586B1

公开(公告)日：2016-10-12

申请号：EP11769393.7

申请日：2011-04-12

申请人： Somalogic, Inc. ,  Otsuka Pharmaceutical Co., Limited

发明人： SCHNEIDER, Daniel, J. ,  HISAMINATO, Akihiko ,  WAUGH, Sheela ,  RESNICOW, Daniel ,  NAGABUKURO, Akira ,  ONO, Toshihide

IPC分类号： C07H19/073 ,  C07H19/10 ,  C07H21/04 ,  C12N15/115

CPC分类号： C07H19/10 ,  C07H19/06 ,  C07H21/04 ,  C12N15/115 ,  C12N2310/335

公开(公告)号：EP3044334A1

公开(公告)日：2016-07-20

申请号：EP14842475.7

申请日：2014-09-08

申请人： Somalogic, Inc.

发明人： JANJIC, Nebojsa ,  DROLET, Daniel W. ,  GELINAS, Amy D. ,  ZHANG, Chi ,  VRKLJAN, Michael

IPC分类号： C12Q1/68

摘要： Aptamers having improved stability against nucleases that bind PDGF and aptamers that bind VEGF are provided. In addition, aptamer constructs comprising a PDGF aptamer and a VEGF aptamer are provided. Pharmaceutical compositions comprising the aptamers and aptamer constructs are provided, as well as methods of treating conditions using the aptamers and aptamer constructs.

摘要翻译： 适体具有改进的稳定性对核酸酶确实结合PDGF和VEGF适体并结合设置。 此外，还提供了包括PDGF适体和VEGF适体适体结构。 药物组合物，其包括被设置在适体和适体的构建体，以及一种使用所述适体和适体的构建体的条件的方法。

公开(公告)号：EP3029153A3

公开(公告)日：2016-07-13

申请号：EP15189622.2

申请日：2011-09-27

申请人： Somalogic, Inc.

发明人： OSTROFF, Rachel M. ,  STEWART, Alex A. E. ,  WILLIAMS, Stephen Alaric ,  BRODY, Edward N. ,  NIKRAD, Malti ,  RIEL-MEHAN, Michael

IPC分类号： C12Q1/68 ,  G01N33/53 ,  G01N33/574

CPC分类号： C12Q1/6886 ,  C12Q2600/158 ,  G01N33/57407 ,  G01N2800/50

摘要： The present disclosure includes biomarkers, methods, devices, reagents, systems, and kits for the detection and diagnosis of cancer generally and mesothelioma specifically. In one aspect, the disclosure provides biomarkers that can be used alone or in various combinations to diagnose cancer generally or mesothelioma specifically. In another aspect, methods are provided for diagnosing mesothelioma in an individual, where the methods include detecting, in a biological sample from an individual, at least one biomarker value corresponding to at least one biomarker selected from the group of biomarkers provided in Table 1, wherein the individual is classified as having mesothelioma, or the likelihood of the individual having mesothelioma is determined, based on the at least one biomarker value. In a further aspect, methods are provided for diagnosing cancer generally in an individual, where the methods include detecting, in a biological sample from an individual, at least one biomarker value corresponding to at least one biomarker selected from the group of biomarkers provided in Table 19, wherein the individual is classified as having cancer generally, or the likelihood of the individual having cancer is determined, based on the at least one biomarker value.

公开(公告)号：EP2836608A4

公开(公告)日：2016-02-24

申请号：EP13774934

申请日：2013-04-12

申请人： SOMALOGIC INC

发明人： OCHSNER URS ,  STERLING DAVID G ,  JANJIC NEBOJSA

IPC分类号： C12Q1/68 ,  G01N33/569

CPC分类号： G01N33/6893 ,  A61K31/496 ,  C12Q1/6883 ,  C12Q2600/106 ,  C12Q2600/158 ,  G01N33/5695 ,  G01N2570/00 ,  G01N2800/52 ,  G01N2800/60

摘要： The present application includes biomarkers, methods, devices, reagents, systems, and kits for the detection, treatment and diagnosis of tuberculosis (TB). In one aspect, the present application includes the identification of biomarkers that can be used alone or in various combinations for the detection of TB, including those set forth in Tables 1, 2, 4, 5, and 8 to 12. In another aspect, the application provides biomarkers that can be used alone or in various combinations to diagnose or prognose TB or follow treatment response. In another aspect, methods are provided for diagnosing TB in an individual, where the methods include detecting, in a biological sample from an individual, at least one biomarker value corresponding to at least one biomarker selected from the group of biomarkers provided in Tables 1, 2, 4, 5, and 8 to 12, wherein the individual is classified as having TB, or the likelihood of the individual having TB is determined, based on the at least one biomarker value.

摘要翻译： 本申请包括用于结核病（TB）的检测，治疗和诊断的生物标志物，方法，装置，试剂，系统和试剂盒。 在一个方面，本申请包括可以单独使用或以各种组合用于检测结核病的生物标志物的鉴定，包括表1,2,4,5和8至12中列出的那些。另一方面， 该应用提供可以单独使用或以各种组合使用以诊断或预测结核病或遵循治疗反应的生物标志物。 在另一方面，提供了用于诊断个体中的结核病的方法，其中所述方法包括在来自个体的生物样品中检测至少一种对应于至少一种生物标志物的生物标记值，所述至少一种生物标志物选自表1， 2，4，5和8至12，其中基于至少一种生物标记值，将个体分类为具有TB或者确定具有TB的个体的可能性。

公开(公告)号：EP2859121A4

公开(公告)日：2015-12-16

申请号：EP13801106

申请日：2013-06-07

申请人： SOMALOGIC INC

发明人： SANDERS GLENN ,  KRAEMER STEPHAN ,  KATILIUS EVALDAS

IPC分类号： C12Q1/68 ,  C07H21/00 ,  G01N33/543

CPC分类号： G01N33/5308 ,  C07H21/00 ,  C12Q1/6804 ,  C12Q1/6811 ,  C12Q1/6837 ,  G01N33/543 ,  G01N33/54306 ,  G01N33/54393 ,  G01N33/68 ,  G01N33/6803 ,  G01N2570/00 ,  C12Q2525/113 ,  C12Q2525/205 ,  C12Q2561/101

摘要： The present disclosure describes methods, devices, reagents, and kits for the detection of one or more target molecules that may be present in a test sample. The described methods, devices, kits, and reagents facilitate the detection and quantification of a non-nucleic acid target (e.g., a protein target) in a test sample by detecting and quantifying a nucleic acid (i.e., an aptamer) where the aptamer-aptamer interactions are significantly reduced or eliminated while maintaining the aptamer-target interaction.